Summary of Radiopharm Theranostics Conference Call Company Overview - **Company Name**: Radiopharm Theranostics - **Stock Symbols**: NASDAQ: RADX, ASX: RAD - **Industry**: Clinical stage radiotherapeutics - **Focus**: Development of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical needs [2][3] Core Business and Partnerships - **Core Business**: Radiopharmaceuticals, with a focus on first-in-class products [3] - **Strategic Partnerships**: - **Lantheus**: Largest shareholder with approximately 15% ownership [3] - **MD Anderson Cancer Center**: Scientific partnership for research and development [3] Pipeline and Clinical Trials - **Clinical Stage Molecules**: Five molecules currently in clinical stage [3] - **Key Products**: - **RAD101**: Imaging agent for brain metastasis, currently in Phase II with over 50% trial recruitment [4][6] - **PD-L1 Nanobody**: In Phase I, targeting multiple solid tumors [10] - **HER2 Nanobody**: In Phase I, targeting breast and gastroesophageal cancer [10] - **RV01**: Monoclonal antibody targeting B7-H3, expected to dose first patient in February [5] - **KLK3-targeting Monoclonal Antibody**: Radiolabeled with Terbium-161, also expected to dose first patient soon [5] Clinical Milestones and Data - **Upcoming Milestones**: - Completion of Phase II enrollment for RAD101 expected by March or April 2026 [14] - Full data release for Phase II anticipated before June 2026 [14] - Significant clinical data for RAD204 and RAD102 expected mid-2026 [14] - **Interim Data**: Positive interim results for RAD101, with 92% of patients achieving primary endpoint [7][8] Market Position and Competition - **Competitive Advantage**: No other radiopharmaceuticals in development for brain metastasis imaging, positioning RAD101 as a first-in-class product [16] - **Comparison with Competitors**: - **Novartis**: Established leader with commercial products but focused on different therapeutic areas [24] - **Telix**: More focused on imaging rather than therapeutics [24] - **Point Biopharma**: Acquired by Lilly, with no direct competition to Radiopharm's pipeline [25] Financial Overview - **Burn Rate**: Approximately $6 million to $7 million per quarter, with sufficient cash to reach Q1 2027 [19] - **Revenue Generation Potential**: RAD101 is closest to commercialization, with potential market launch by 2029 [21] Supply Chain and Manufacturing - **Isotope Supply Chain**: Multiple suppliers secured for Lutetium-177 to ensure reliable supply [18] Strategic Vision - **Partnership Strategy**: Focus on clinical development with openness to partnerships or licensing as trials progress [27] - **Long-term Goals**: Aim to deliver clinical data in 2026 that supports future financing needs [19][29] Conclusion - **Outlook**: 2026 is expected to be a pivotal year for Radiopharm Theranostics, with a strong focus on execution and addressing unmet medical needs in cancer treatment [29]

Core Insights - ASP Isotopes Inc. has made significant advancements in its business development, including a major supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in Florida to enhance its operations in nuclear medicine [1][2][3] Supply Agreement for Enriched Silicon-28 - The company has entered into its largest supply contract for enriched silicon-28 with a U.S.-based customer, with deliveries expected in Q1 2026 [2][4] - Enriched silicon-28 is crucial for solid-state quantum computing and advanced semiconductor technologies, providing a noise-free environment for qubits, which enhances device performance [5][6] - The growing demand for high-purity silicon-28 is driven by increased global investment in quantum computing and advanced electronics [6][7] Acquisition of Radiopharmacy - The company has acquired an independent radiopharmacy in Florida, marking PET Labs' first expansion outside South Africa [3][8] - This acquisition aims to enhance PET Labs' nuclear medicine business and is expected to be accretive to revenues, EBITDA, and EPS in 2026 [3][8] - The Florida facility currently offers SPECT services, with plans to introduce PET services by 2027, which is anticipated to boost future revenues and profits [8] Strategic Expansion Plans - The company is pursuing further expansion of PET Labs in the U.S. and other regions to meet the rising demand for radiodiagnostics and radiotherapeutics [9][10] - PET Labs aims to establish a vertically integrated radiopharmacy network capable of producing stable isotopes for radioisotope production, providing a competitive edge in the market [10] - The CEO of PET Labs has indicated plans for both brownfield and greenfield expansions to position the company as a global leader in radioisotope production for oncology treatments [11]

Core Insights - IsoBio, Inc. is focused on developing a pipeline of monoclonal antibody-based radioisotope therapeutics targeting both derisked and novel tumor antigens for cancer treatment [1][3] - The company has successfully closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. [1][3] Company Overview - IsoBio is a U.S.-based radiotherapeutic development company that specializes in antibody-isotope conjugates (AICs) [1][12] - The company plans to establish offices in Seattle, WA, and Gladwyne, PA [2][6] - IsoBio's management team is led by Bruce Turner, M.D., Ph.D., who has extensive experience in the biotech industry [6][7] Strategic Collaboration - IsoBio has formed a strategic partnership with ASP Isotopes Inc. and its nuclear medicine subsidiary, PET Labs, to enhance manufacturing capabilities and reduce supply chain uncertainties for isotopes [2][4] - This collaboration aims to leverage ASP Isotopes' technology and global manufacturing capabilities to develop novel isotopes for radiotherapeutics [2][4] Product Development - IsoBio is developing radiotherapeutics that include Lutetium-177, Actinium-225, Terbium-161, and other undisclosed novel radioisotopes [5] - The company utilizes proprietary linker and conjugation technology to create highly potent AICs, which provide targeted treatment for difficult-to-treat tumors [5][12] Market Context - The supply chain for radiotherapeutics has faced challenges due to limited availability of commonly used isotopes, making IsoBio's strategic partnership advantageous [4] - There is a growing demand for innovative cancer therapies, and IsoBio's focus on targeted therapies aligns with this market need [3][4]